TGA approves first non-hormonal menopause drug for hot flushes
Dr Karen Magraith says fezolinetant will most likely benefit women who cannot use menopausal hormone therapy.
GPs can now prescribe the non-hormonal menopause drug fezolinetant to women with moderate to severe vasomotor symptoms, following TGA approval of the first-of-its-kind treatment.
The once-daily pill contains 45mg fezolinetant (Veoza), which is a selective neurokinin-3 receptor agonist that acts on the thermoregulatory centre in the hypothalamus.
